Introduction: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a lymphoid neoplasm of with heterogeneous cytogenetic and molecular abnormalities that are used for prognostication. We aimed to do a clinic-pathological study of CLL/SLL with complex karyotype (≥3 abnormalities) and assess risk of Richter transformation. Methods: We identified 333 patients with CLL/SLL having complex karyotype at a single institution from January 1969 to December 31, 2015. Clinicopathological parameters were extracted from institutional databases. Logistic regression (SAS 9.4) was applied to test association between parameters and transformation. Results: Median age was 64 years. Patients included 250 men (75.01%) and 83 women (83%). Laboratory parameters were as follows (median [range]): Hb 11.1 (9.6-12.7) g/ dL, WBC 20.6 (7.2-70.9) K/uL, platelets 100 (50-160) K/ uL, absolute lymphocyte count 14.96 (3.93-61.11) K/uL, LDH 698 (547-939) IU/L, B2 microglobulin 4.7 (3.2-6.6). Splenomegaly was present in 97 (29.13%) patients, bulky lymphadenopathy in 20 (6.01%). In patients that had results available, CLL cells were positive for ZAP70 in 71% and CD38 in 182 (64.76%) patients. VH mutation was present in 42 (14%). Cytogenetic abnormalities were as follows: -17 in 20 (5.70%), trisomy 12 in 56 (16.82%). A total of 39 patients developed Richter transformation; of these 24 (61.54%) were men and 15(38.46%) women, and median age at time of transformation was 59.5 years. Of 31 patients with survival data, median survival time for Richter transformation was 6.91 years as compared to 7.9 years for 147 subjects without. Only Hb was associated with increased risk of developing Richter transformation. Conclusion: CLL/SLL with complex karyotype is a heterogeneous disease at the genetic level. Only Hb was associated with risk for Richter transformation. Introduction: Myeloid sarcoma without bone marrow (BM) involvement is a rare phenomenon. In the literature, it has been reported that myeloid sarcoma harboring the CBFB-MYH11 fusion should be considered in cases with small bowel/abdomen presentation (Huang et al 2014) . Anecdotally, we have noted similar cases and report herein their clinicopathologic features. Methods: Cases of myeloid sarcoma in the small bowel/ abdomen with CBFB-MYH11 fusion by FISH were identified from our cytogenetic database (2010)(2011)(2012)(2013)(2014)(2015)(2016). A dualcolor/dual-fusion probe set targeted the CBFB and MYH11 genes on formalin-fixed, paraffin-embedded tissue sections. The clinical features, morphology, immunophenotype, and BM involvement were collected. Results: Ten cases of myeloid sarcoma with CBFB-MYH11 fusion in the small bowel/abdomen were identified. The M:F ratio was 4:6 with median age of 35 (range 15-54 years). The involved sites included small intestine/ ileum (5), duodenum (2), omentum (2), and pancreas/gallbladder (1). Morphologically, there was a heterogeneous appearance to the blastic infiltrate ranging from small to large cells and slight to prominent irregular nuclei. An admixed eosinophilic component was seen in five of 10 cases. Immunophenotypically, all cases were assessed via immunohistochemistry, with two cases having fresh tissue for flow cytometry. CD34, CD117, and MPO were expressed in seven of eight cases, nine of nine cases, and eight of eight cases, respectively. In eight of eight cases, there was no morphologic/immunophenotypic/genetic evidence of BM involvement. Conclusions: At presentation, isolated myeloid sarcoma in the small bowel/abdomen should be strongly considered for evaluation of the CBFB-MYH11 fusion recurring genetic abnormality. Importantly, the usual morphologic clue of admixed eosinophils is absent 50% of the time. Given that fresh tissue is typically not available, the diagnostic workup requires immunohistochemistry and genetic assessment via FISH on paraffin sections. In our series, patients' average age is mid-30s, and concurrent BM involvement is unlikely.
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